Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:INSY

INSYS Therapeutics (INSY) Stock Price, News & Analysis

INSYS Therapeutics logo

About INSYS Therapeutics Stock (NASDAQ:INSY)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.23
$65,799,000.00
52-Week Range
N/A
Volume
N/A
Average Volume
9.52 million shs
Market Capitalization
$21.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive INSY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INSYS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INSY Stock News Headlines

When the levee breaks
The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.
Aldeyra Therapeutics, Inc. (ALDX)
See More Headlines

INSY Stock Analysis - Frequently Asked Questions

INSYS Therapeutics, Inc. (NASDAQ:INSY) announced its quarterly earnings data on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.33. The firm's revenue was down 68.1% on a year-over-year basis.

INSYS Therapeutics's stock split before market open on Monday, March 31st 2014.The 3-2 split was announced on Tuesday, March 4th 2014. The newly minted shares were distributed to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of stock prior to the split would have 150 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that INSYS Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Puma Biotechnology (PBYI), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Incyte (INCY) and BioMarin Pharmaceutical (BMRN).

Company Calendar

Last Earnings
5/10/2019
Today
8/17/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INSY
Previous Symbol
NASDAQ:NEOL
CIK
1516479
Fax
N/A
Employees
226
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.39)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$124.51 million
Net Margins
-346.61%
Pretax Margin
N/A
Return on Equity
-1,430.37%
Return on Assets
-64.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.54
Quick Ratio
0.50

Sales & Book Value

Annual Sales
$82.08 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.58) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
74,570,000
Free Float
N/A
Market Cap
$21.71 million
Optionable
Optionable
Beta
3.21
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:INSY) was last updated on 8/18/2025 by MarketBeat.com Staff
From Our Partners